Research programme: anticancer therapeutics - Florida Atlantic University

Drug Profile

Research programme: anticancer therapeutics - Florida Atlantic University

Alternative Names: SIM2 inhibitors - Affitech/FAU

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Florida Atlantic University
  • Developer Florida Atlantic University; Torrey Pines Institute for Molecular Studies
  • Class Antisense elements
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in USA
  • 08 May 2007 Florida Atlantic University and Torrey Pines Institute for Molecular Studies are collaborating in the development of SIM2 inhibitors
  • 19 Jun 2003 A preclinical study has been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top